• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Edgewise Therapeutics (EWTX) Valuation After Promising Sevasemten Becker Muscular Dystrophy Data

    Simply Wall St·03/21/2026 12:04:59
    Listen to the news

    Edgewise Therapeutics (EWTX) recently reported long term MESA extension data for its lead candidate sevasemten in Becker muscular dystrophy, showing functional stabilization over 3.5 years versus the decline typically seen in natural history data.

    See our latest analysis for Edgewise Therapeutics.

    The recent Becker muscular dystrophy data arrives after a strong run, with a 90 day share price return of 13.74% and a 3 year total shareholder return above 3x. However, the 1 month share price return of 3.62% and 1 day move of 3.29% show some cooling in momentum around the current US$29.06 level.

    If this type of clinical progress has your attention, it can be useful to see what else is moving in related areas and scan 35 healthcare AI stocks.

    With shares at around US$29.06 after a multi year run and a value score of 1, investors now face a simple question: is Edgewise still pricing in too little of sevasemten’s potential, or is future growth already in the stock?

    Preferred Price to Book of 6x: Is It Justified?

    At around $29.06 per share, Edgewise Therapeutics trades at a P/B of 6x, which is well above the broader US Pharmaceuticals industry average of 2x, but below its more closely matched peer group average of 22.3x.

    The P/B ratio compares the market value of the company to its accounting book value. This can be a useful reference point for a clinical stage biotech where revenue is minimal and earnings are negative. With Edgewise reporting a loss of $167.795 million and less than $1 million in revenue, most of the market value is tied to expectations for its pipeline rather than current financial performance.

    The gap between the 6x P/B for Edgewise and the 2x industry average suggests investors are assigning a premium for its muscle disorder pipeline. The discount to the 22.3x peer average, by contrast, indicates that relative to a more concentrated comparator group the market is applying some restraint. For anyone weighing that tension between premium and discount, the 6x level is the point the market could move away from if sentiment or data meaningfully shifts.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 6x (ABOUT RIGHT)

    However, there are clear pressure points too, including recent 1 month and 7 day share price declines, as well as the reliance on successful outcomes from multiple ongoing trials.

    Find out about the key risks to this Edgewise Therapeutics narrative.

    Next Steps

    If this mix of premium pricing and clinical promise feels finely balanced, do not wait to form an opinion. Review the data, then weigh the 3 important warning signs.

    Looking for more investment ideas?

    If Edgewise has sharpened your focus on opportunity and risk, do not stop here. Broaden your watchlist now or you will likely miss compelling setups.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.